Last reviewed · How we verify
Ferriprox®
Ferriprox®, marketed by ApoPharma, is an iron chelator with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and therapeutic efficacy for its primary indication. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Ferriprox® |
|---|---|
| Also known as | DFP, Deferiprone, L1 |
| Sponsor | ApoPharma |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias (PHASE4)
- Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias (PHASE4)
- Observational Study of Deferiprone (Ferriprox®) in the Treatment of Superficial Siderosis
- Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration (PHASE1)
- Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease (PHASE1)
- Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects (PHASE4)
- An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers (PHASE4)
- Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™ (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ferriprox® CI brief — competitive landscape report
- Ferriprox® updates RSS · CI watch RSS
- ApoPharma portfolio CI